Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Richard Cohen, the husband of former TODAY anchor Meredith Vieira, died on Christmas Eve at the age of 76. Cohen lived with ...

Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Richard Cohen, veteran CBS News journalist and the husband of former Today cohost Meredith Vieira, has died after more than 50 years of battling multiple sclerosis. The former senior producer passed ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Denali Therapeutics (DNLI) to $87 from $90 and keeps a Buy rating on the ...

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...